MediGene Signs Veregen Commercialization Agreement with SynCore Bio in Taiwan

24-May-2011 - Taiwan

MediGene AG  has signed an exclusive license and supply agreement with SynCore Bio, a subsidiary of the Sinphar Group, for the commercialization and marketing of Veregen® ointment in Taiwan for the treatment of genital warts. MediGene will supply Sinphar with API, Sinphar will produce the drug in its Taiwan manufacturing facilities and SynCore Bio will market and sell the ointment in Taiwan. Financial details of the agreement were not disclosed.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances